Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
TG Therapeutics, Inc. (TGTX) had Normalized Pre-Tax Income of $107.39M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$616.29M |
|
$447.18M |
|
$100.71M |
|
$515.57M |
|
$492.96M |
|
$123.32M |
|
$-15.93M |
|
$107.39M |
|
|
Normalized Pre-Tax Income |
$107.39M |
$447.18M |
|
$447.18M |
|
$447.18M |
|
$447.18M |
|
$123.32M |
|
$123.32M |
|
144.32M |
|
161.41M |
|
$3.10 |
|
$2.77 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
$0.00M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Cash Flow Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|